Open AccessEfficacy and Safety of Tirofiban in High‐Risk Patients With Non‐ST‐Segment Elevation Acute Coronary Syndromes
Author(s) -
Yan Zhenxian,
Zhou YuJie,
Zhao Yingxin,
Li Yueping,
Nie Xiaomin,
Zhou Zhiming,
Jia Dean
Publication year - 2009
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.20475
Subject(s) - medicine , tirofiban , st segment , cardiology , elevation (ballistics) , acute coronary syndrome , st elevation , electrocardiography , percutaneous coronary intervention , myocardial infarction , geometry , mathematics
Objective To evaluate the safety and efficacy of tirofiban in high risk patients with non‐ST‐segment elevation acute coronary syndromes (NSTE‐ACS) after percutaneous coronary intervention (PCI). Methods A total of 240 patients were randomized to either a tirofiban group or a control group. Results Compared with the control group, the platelet aggregation rate in the tirofiban group was lower ( P < 0.01); the plasma levels of CK‐MB and troponin I, cardiac form (cTnI) were lower ( P < 0.05); ECG improved significantly ( P < 0.05); the incidence of major adverse cardiac events (MACE) was lower ( P < 0.05); and there was no difference in bleeding complications between the 2 groups ( P = 0.1). Conclusions The administration of tirofiban in high risk patients with NSTE‐ACS after PCI is safe and effective. Copyright © 2009 Wiley Periodicals, Inc.